Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.
- Published In:
- Arthritis and rheumatism, 58(12), 3873-83 (2008)
- Authors:
- Muller, Sylviane, Monneaux, Fanny, Schall, Nicolas, Rashkov, Rasho K, Oparanov, Boycho A, Wiesel, Philippe, Geiger, Jean-Marie, Zimmer, Robert
- Database ID:
- RPEP-01389
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01389APA
Muller, Sylviane; Monneaux, Fanny; Schall, Nicolas; Rashkov, Rasho K; Oparanov, Boycho A; Wiesel, Philippe; Geiger, Jean-Marie; Zimmer, Robert. (2008). Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.. Arthritis and rheumatism, 58(12), 3873-83. https://doi.org/10.1002/art.24027
MLA
Muller, Sylviane, et al. "Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.." Arthritis and rheumatism, 2008. https://doi.org/10.1002/art.24027
RethinkPeptides
RethinkPeptides Research Database. "Spliceosomal peptide P140 for immunotherapy of systemic lupu..." RPEP-01389. Retrieved from https://rethinkpeptides.com/research/muller-2008-spliceosomal-peptide-p140-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.